Dinutuximab-BETA:

         EMA Approved

  • Dinutuximab-beta is a monoclonal anti – GD2 antibody indicated for the treatment of newly diagnosed, relapsed and refractory high-risk neuroblastoma.
  • It is a form of immunotherapy which binds to GD-2, which is over-expressed in neuroblastoma cells and induces antibody and complement-mediated cytotoxicity to eradicate tumor cells. 

For any medical enquiry,

Contact us at  +91 9591736262 or
Email us at info@sayretherapeutics.com